What is Optune Gio ® approved to treat? Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 ...
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most ...
Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend survival in some of the most ...
Good day, and thank you for standing by. Welcome to the NovoCure's Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand ...
Investor's Business Daily on MSN
Two medical stocks skyrocket after demolishing views — and one is about to break out
Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NovoCure Limited before investing. In this article, we go over a few key elements ...
The three most common types of brain tumour are intracranial metastases, which spread from other primary sites of disease; meningiomas, which are mostly benign; and glioblastoma multiforme (GBM), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results